Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Toronto Dominion Bank

Toronto Dominion Bank trimmed its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 29.5% in the 2nd quarter, HoldingsChannel reports. The firm owned 96,706 shares of the medical equipment provider’s stock after selling 40,531 shares during the quarter. Toronto Dominion Bank’s holdings in Hologic were worth $7,180,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Price T Rowe Associates Inc. MD lifted its stake in Hologic by 77.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 6,297,197 shares of the medical equipment provider’s stock valued at $490,931,000 after buying an additional 2,753,016 shares in the last quarter. Black Creek Investment Management Inc. raised its holdings in shares of Hologic by 60.9% during the second quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider’s stock valued at $173,669,000 after acquiring an additional 885,524 shares during the period. Dimensional Fund Advisors LP lifted its position in shares of Hologic by 5.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,326,992 shares of the medical equipment provider’s stock valued at $172,780,000 after acquiring an additional 124,739 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its stake in Hologic by 4.0% in the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,271,603 shares of the medical equipment provider’s stock worth $168,666,000 after purchasing an additional 87,176 shares during the period. Finally, The Manufacturers Life Insurance Company grew its position in Hologic by 117.4% during the 4th quarter. The Manufacturers Life Insurance Company now owns 2,163,718 shares of the medical equipment provider’s stock worth $154,598,000 after purchasing an additional 1,168,564 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Wall Street Analyst Weigh In

HOLX has been the subject of several recent analyst reports. Evercore ISI raised their target price on Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a research report on Tuesday, July 30th. Needham & Company LLC reaffirmed a “buy” rating and set a $90.00 target price on shares of Hologic in a research note on Tuesday, September 17th. StockNews.com downgraded Hologic from a “strong-buy” rating to a “buy” rating in a report on Friday. Stephens restated an “overweight” rating and set a $92.00 price target on shares of Hologic in a report on Tuesday, July 30th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Hologic from $91.00 to $95.00 and gave the company an “overweight” rating in a research note on Tuesday, July 30th. Four equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, Hologic has an average rating of “Moderate Buy” and an average target price of $87.60.

Hologic Stock Up 0.9 %

HOLX stock opened at $80.82 on Friday. The firm has a market cap of $18.86 billion, a PE ratio of 41.23, a PEG ratio of 2.58 and a beta of 0.98. Hologic, Inc. has a 1 year low of $64.02 and a 1 year high of $84.67. The company has a fifty day simple moving average of $81.08 and a 200 day simple moving average of $77.28. The company has a current ratio of 3.99, a quick ratio of 3.32 and a debt-to-equity ratio of 0.51.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.04. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The company had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. During the same quarter in the prior year, the company posted $0.93 EPS. The firm’s revenue was up 2.7% on a year-over-year basis. Sell-side analysts anticipate that Hologic, Inc. will post 4.09 EPS for the current fiscal year.

Insider Activity

In related news, insider Brandon Schnittker sold 476 shares of the company’s stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total transaction of $39,560.36. Following the completion of the sale, the insider now directly owns 3,735 shares of the company’s stock, valued at approximately $310,415.85. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In related news, insider Benjamin Jordan Cohn sold 5,093 shares of the stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $81.99, for a total transaction of $417,575.07. Following the completion of the sale, the insider now owns 10,476 shares in the company, valued at approximately $858,927.24. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Brandon Schnittker sold 476 shares of Hologic stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $83.11, for a total value of $39,560.36. Following the completion of the transaction, the insider now directly owns 3,735 shares in the company, valued at $310,415.85. The disclosure for this sale can be found here. Insiders have sold a total of 18,280 shares of company stock valued at $1,469,973 over the last 90 days. 1.75% of the stock is currently owned by company insiders.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.